Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time. The inclusion of these Pfizer compounds provides authentic material that will help advance researchers’ understanding of biological systems.
Sigma-Aldrich said that the Pfizer compounds will be sold worldwide directly as in-stock, pre-packaged items and, upon request, in bulk, and will also be mapped to genes and associated pathways and interactors via Sigma-Aldrich’s online search platform ‘Your Favorite Gene powered by Ingenuity.’ While the initial agreement includes approximately 100 Pfizer compounds, Sigma-Aldrich expects to add further Pfizer compounds on a regular basis.
David Smoller, president of research biotech business unit at Sigma Life Science, said: “This multi-compound deal not only enriches our extensive portfolio of products with authentic Pfizer material but provides valuable resources that will enable our customers to modulate their protein targets, facilitating further advances in cellular and pathway biology.”
Rick Connell, vice president and worldwide head of external research solutions center of excellence at Pfizer, said: “Working with Sigma-Aldrich we are able to make authentic Pfizer compounds more readily available to the research community.”